| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_845dee65a3b9073bfd5dd429d700d189
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_096a7ce6f20587c686ba77f6a59ea0fa |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 |
| filingDate |
2020-09-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_54aa1e2f6a074e4eb1ebf21010f638a5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e65270b3cc85a841e811ed8c8b9c3fa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_37aa23c453c9492f3dda860b0b531e26 |
| publicationDate |
2022-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2022340554-A1 |
| titleOfInvention |
Thioridazine derivatives and their use for the treatment of cancer |
| abstract |
The present invention relates to novel thioridazine analogue compounds of formula (I): wherein R1 is OCH3 or NH2, particularly suitable to be used in the treatment of pediatric acute myeloid leukemia harboring the t(6;11)(q27;q23) KMT2A/AFDN rearrangement. |
| priorityDate |
2019-09-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |